DK0772451T3 - Behandling af type II-diabetes mellitus med amylin-agonister - Google Patents

Behandling af type II-diabetes mellitus med amylin-agonister

Info

Publication number
DK0772451T3
DK0772451T3 DK96921467T DK96921467T DK0772451T3 DK 0772451 T3 DK0772451 T3 DK 0772451T3 DK 96921467 T DK96921467 T DK 96921467T DK 96921467 T DK96921467 T DK 96921467T DK 0772451 T3 DK0772451 T3 DK 0772451T3
Authority
DK
Denmark
Prior art keywords
diabetes mellitus
type
treatment
amylin agonists
amylin
Prior art date
Application number
DK96921467T
Other languages
Danish (da)
English (en)
Inventor
Orville G Kolterman
Robert G Thompson
John F Mullane
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of DK0772451T3 publication Critical patent/DK0772451T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK96921467T 1995-06-07 1996-06-07 Behandling af type II-diabetes mellitus med amylin-agonister DK0772451T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/483,188 US6143718A (en) 1995-06-07 1995-06-07 Treatment of Type II diabetes mellutis with amylin agonists
PCT/US1996/009875 WO1996040220A1 (en) 1995-06-07 1996-06-07 Treatment of type ii diabetes mellitus with amylin agonists

Publications (1)

Publication Number Publication Date
DK0772451T3 true DK0772451T3 (da) 2003-01-06

Family

ID=23919034

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96921467T DK0772451T3 (da) 1995-06-07 1996-06-07 Behandling af type II-diabetes mellitus med amylin-agonister

Country Status (19)

Country Link
US (2) US6143718A (ko)
EP (1) EP0772451B1 (ko)
JP (1) JP4009319B2 (ko)
AT (1) ATE228849T1 (ko)
AU (1) AU721489B2 (ko)
BG (1) BG101230A (ko)
CA (1) CA2196999C (ko)
CZ (1) CZ289043B6 (ko)
DE (1) DE69625157T2 (ko)
DK (1) DK0772451T3 (ko)
ES (1) ES2187659T3 (ko)
HU (1) HUP9700368A3 (ko)
IN (1) IN181672B (ko)
NO (1) NO970519L (ko)
PT (1) PT772451E (ko)
RU (1) RU2166958C2 (ko)
SK (1) SK18697A3 (ko)
WO (1) WO1996040220A1 (ko)
ZA (1) ZA964838B (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US6114304A (en) * 1993-09-07 2000-09-05 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
DK1044015T3 (da) * 1998-01-09 2008-12-08 Amylin Pharmaceuticals Inc Formuleringer med amylinagonistpeptider og insulin
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
ATE412421T1 (de) * 2002-01-08 2008-11-15 Amylin Pharmaceuticals Inc Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
PL374860A1 (en) * 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
AU2004241242A1 (en) * 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
WO2005014022A1 (en) * 2003-07-16 2005-02-17 Develogen Aktiengesellschaft Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US20050209148A1 (en) * 2004-02-20 2005-09-22 Arnon Rosenthal Methods of treating obesity or diabetes using NT-4/5
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
WO2006099288A2 (en) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
CA2637707A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
RU2008131939A (ru) * 2006-02-02 2010-02-10 Ринат Ньюросайенс Корп. (Us) Способы лечения нежелательной потери веса или нарушений приема пищи агонистами trkb
EP2114436A1 (en) * 2006-12-20 2009-11-11 Rinat Neuroscience Corp. Trkb agonists for treating autoimmune disorders
CN101939022A (zh) * 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
EP2303226B1 (en) 2008-06-25 2016-03-23 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
CA2729139C (en) * 2008-06-25 2016-07-26 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
MX2011009559A (es) * 2009-03-12 2012-01-12 Nordic Bioscience As Tratamiento de la diabetes y el sindrome metabolico.
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
ES2887370T3 (es) * 2014-09-04 2021-12-22 Novo Nordisk As Nuevo agonista del receptor de amilina y calcitonina
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
CA2100745C (en) * 1991-11-19 2007-07-31 Laura S. L. Gaeta Amylin agonist peptides and uses therefor
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US6114304A (en) * 1993-09-07 2000-09-05 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides

Also Published As

Publication number Publication date
ES2187659T3 (es) 2003-06-16
WO1996040220A1 (en) 1996-12-19
BG101230A (en) 1997-10-31
DE69625157T2 (de) 2003-04-17
SK18697A3 (en) 1998-02-04
JP4009319B2 (ja) 2007-11-14
EP0772451B1 (en) 2002-12-04
HUP9700368A2 (hu) 1998-06-29
NO970519L (no) 1997-04-07
CA2196999A1 (en) 1996-12-19
HUP9700368A3 (en) 2001-03-28
HU9700368D0 (en) 1997-04-28
RU2166958C2 (ru) 2001-05-20
EP0772451A1 (en) 1997-05-14
NO970519D0 (no) 1997-02-05
ZA964838B (en) 1997-02-24
CZ33797A3 (en) 1997-07-16
JPH10503785A (ja) 1998-04-07
PT772451E (pt) 2003-04-30
US6417164B1 (en) 2002-07-09
IN181672B (ko) 1998-08-29
US6143718A (en) 2000-11-07
ATE228849T1 (de) 2002-12-15
DE69625157D1 (de) 2003-01-16
EP0772451A4 (en) 1998-09-30
AU6268596A (en) 1996-12-30
CZ289043B6 (cs) 2001-10-17
CA2196999C (en) 2012-09-04
AU721489B2 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
DK0772451T3 (da) Behandling af type II-diabetes mellitus med amylin-agonister
EA200200503A1 (ru) Способ лечения ревматоидного артрита
EA199800316A1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
DK0840601T3 (da) THIP til behandling af søvnforstyrrelser
AU1718400A (en) Method for treating pain
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
DK0514452T4 (da) Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
EE03202B1 (et) Intravaginaalne manustussüsteem ja selle valmistamismeetod
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
DE68910799D1 (de) Faserbehandlungszusammensetzung.
DK0863760T3 (da) Anvendelse af forbindelser med antimineralcorticoid virkning over for narkotikafvænning
DE69112166D1 (de) Plasmaquellenvorrichtung für Ionenimplantierung.
FI951511A0 (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE69104448D1 (de) Faserbehandlungsmittelzusammensetzung.
DK322583D0 (da) Middel til behandling af sar
EA200100133A1 (ru) Оксазолидиноны для лечения инфекционных болезней глаз
PT888330E (pt) Metodos de tratamento ou prevencao de cistite intersticial
DE68913088D1 (de) Faserbehandlungszusammensetzung.
DK0517787T3 (da) Fremgangsmåde til behandling af terapiresistent skizofreni med amperozide
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
EA199800822A1 (ru) Способ лечения избыточной агрессии
KR920001467U (ko) 결합식 용액 주입기(syinge)용 팁(tip)
EA199800818A1 (ru) Способ лечения бессонницы
EA200000418A1 (ru) Применение тиазолидиндионов для лечения гипергликемии